Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
NCI-CCC Tumor Board Question
•
Hematology
•
UC Irvine
•
NCI-CCC Lymphoma Tumor Board Question
Is there a role for thiotepa-based auto transplant for consolidation in PCNSL if the patient had progression on both MTX and Ara-C?
The disease is better controlled after radiation.
Related Questions
How would you manage a patient with primary CNS lymphoma who received R-MTX followed by autologous transplant with systemic relapse 5 years later for which R-Pola-CHP was given now followed by CNS relapse?
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
How would you manage a frail patient with GCB DLBCL who is unable to complete R-CHOP but has moderate residual disease?
How would you manage a patient with marginal zone lymphoma who progress after treatment on a BKTI?
How would you manage a patient with a recent diagnosis of advanced DLBCL (non-GCB subtype) who has baseline grade 3 neuropathy?
Do you utilize ctDNA-based MRD testing after frontline chemotherapy for DLBCL?
How would you structure your monitoring for a low-risk leukemic TP53-negative mantle cell lymphoma with 5% MCL cells detected in both peripheral blood and bone marrow, mild splenomegaly, and no lymphadenopathy or B symptoms?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
How do you approach patient with CLL/SLL limited to the prostate?